Pfizer (NYSE:PFE) Reaches New 1-Year High Following Analyst Upgrade

Pfizer Inc. (NYSE:PFE) reached a new 52-week high on Thursday after UBS Group raised their price target on the stock from $27.00 to $30.00. UBS Group currently has a neutral rating on the stock. Pfizer traded as high as $31.44 and last traded at $31.2880, with a volume of 8,851,793 shares changing hands. The stock had previously closed at $30.79.

Several other equities research analysts have also recently weighed in on the company. HSBC increased their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, September 10th. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Royal Bank Of Canada boosted their price objective on shares of Pfizer from $25.00 to $28.00 and gave the stock a “sector perform” rating in a report on Wednesday. JPMorgan Chase & Co. raised their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Five equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $29.81.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat Q3 earnings and revenue expectations and raised its 2026 forecast to $62–$64 billion in revenue and adjusted EPS of $2.95–$3.05. Launched and acquired products grew 32% operationally, while non-COVID products rose 7%. Article: Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Scotiabank raised its price target to $35 and reiterated “sector outperform,” adding to the positive outlook surrounding the results. Scotiabank analyst recommendations
• Positive Sentiment: A recent TipRanks article described Pfizer’s dividend as well-covered and the stock’s valuation as modest, potentially appealing to income-focused investors. Article: Pfizer Stock Looks Attractive for Income Investors
• Neutral Sentiment: Analyst views remain mixed: RBC raised its target to $28 and UBS and Citi to $30, but all maintained neutral or sector-perform ratings—targets below the price cited in the reports. RBC analyst recommendations
• Negative Sentiment: Revenue was roughly flat as COVID product sales continued to decline, and margin pressure remains a concern. Pfizer must sustain growth in newer products and deliver on cost savings and pipeline milestones to make the raised outlook durable. Article: Pfizer Just Raised Guidance. The Bigger Test Comes Next

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE purchased a new stake in shares of Pfizer during the 2nd quarter worth $1,049,602,000. BlackRock Inc. boosted its holdings in shares of Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares during the last quarter. Nykredit A S acquired a new position in shares of Pfizer in the 2nd quarter valued at $205,774,000. Assenagon Asset Management S.A. increased its stake in shares of Pfizer by 96.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock valued at $286,609,000 after purchasing an additional 5,829,204 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after buying an additional 5,501,032 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 1.5%

The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The firm has a market capitalization of $178.09 billion, a PE ratio of 44.58, a P/E/G ratio of 2.04 and a beta of 0.31. The company’s fifty day simple moving average is $28.69 and its 200-day simple moving average is $26.86.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.74 by $0.13. Pfizer had a return on equity of 19.98% and a net margin of 6.34%. The company had revenue of $16.58 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the business earned $0.87 EPS. Pfizer’s quarterly revenue was down .4% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 5.5%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is currently 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.